properly and therefore surgical intervention using autografts or allografts is necessary. Currently, autografts are the gold standard; however, they are associated with donor site morbidity, increased pain, high cost, and long patient recovery time. The alternative is to use allografts, but they carry the risk of immunogenicity, infectious agents, and lack the osteoinductive capacity of autografts. [1] To overcome these limitations there has been a vast effort to develop new biomaterials to aid large bone defect repair. Among these materials, natural biomaterials have been widely studied due to their advantages, such as biodegradability, biocompatibility, and the ability to interact with the extracellular matrix and cells. [2] Injectable formulations are preferred over implants for the treatment of defects that do not require operational fixation since the application is easier and the patient will not suffer from surgery and consequently, achieve a faster recovery. Moreover, in the case of irregular bone defects, injectable scaffolds might be advantageous because they can adapt to the defect shape better. [3] Alginate, hyaluronic acid (HA), and collagen derived materials have been investigated as scaffolds, particles, and in situ gelling hydrogels. [4] Materials can be combined with bone forming proteins such as bone morphogenetic protein 2 (BMP-2) to stimulate bone 
www.advancedsciencenews.com www.advhealthmat.de formation. BMP-2 is considered to be one of the most powerful osteoinductive factors and is the only bone morphogenetic protein (loaded in a collagen sponge) approved and currently used as a bone graft substitute. [5] However, large doses of BMP-2 are needed to produce a significant osteogenic effect. [6] The major reason for this is the burst-release of the protein from the collagen sponge. Half of the BMP-2 was released in the first two days in vivo in a rabbit ulna osteotomy model. [7] This often results in undesired ectopic bone formation, soft tissue swelling and bone resorption. [8] Therefore, a biomaterial that can provide a slower protein release may perform better in clinics, eliminating adverse effects. There are several challenges for developing a suitable protein carrier material. [9] It should promote the recruitment of skeletal and endothelial progenitor cells and trigger their differentiation to mature osteoblasts and endothelial cells with a minimum amount of loaded protein.
Recombinant collagen-like peptide (RCP) material and its use for tissue engineering have been investigated by several studies, showing an optimum pore size and porosity for osteoconduction and high cell viability. [10] RCP does not only facilitate the cell attachment by its arginylglycylaspartic acid (RGD) rich peptide sequence [10a] but can also be expected to decrease the risk of immune reaction due to its animal free origin compared to other collagen based products. In fact, RCP is produced under good manufacturing process conditions within the facilities of Fujifilm. The use of RGD rich microspheres comprised of RCP (RCP-MS) for the stimulation of cell attachment is very important when using materials where cell attachment is suboptimal, such as alginates and HA. We have previously investigated the use of recombinant collagen-like peptide microspheres for slow release of BMP-2. In that study, we optimized the water uptake in the RCP-MS for BMP-2-loading. Particle size before and after swelling was also assessed by rheology, showing a similar storage and loss modulus, which indicated that the material was not degraded. Therefore, RCP-MS were intact for 2 weeks in cell culture medium and were only degraded when collagenase treatment was applied. [10c] In light of these results, here we aim to develop and test 3 in situ gelling formulations, based on alginate and hyaluronic acid to retain BMP-2 releasing microspheres, resulting in slow localized growth factor release.
In a search for an injectable hydrogel system to deliver BMP-2 carrying RCP-MS, we have investigated two potential systems: one system that could be cross-linked and form a network in the presence of ions, and another system that could change conformation with a temperature switch. These two systems were alginate and poly(N-isopropylacrylamide) (PNIPAM) modified hyaluronic acid (HApN) respectively, both widely used in bone tissue engineering.
Alginate is a polysaccharide composed of β-D-mannuronic acid (M-block) and α-L-guluronic acid (G-block) monomers. Several studies have demonstrated the potential of this hydrogel for bone tissue engineering. [11] Mineralization of alginate has also been characterized by Raman spectroscopy. [12] Alginate in situ gelling formulations have been developed in combination with particles and in vitro experiments showed the potential of the formulations for drug delivery. [13] Previously, alginate hydrogel with gelatin microspheres loaded with BMP-2 was used to study osteogenesis in vivo. However, the formulations could not induce bone formation probably due to fast degradation of material; and only after addition of biphasic calcium phosphate granules, was the bone formation achieved. [14] There are various types of alginate and it is known that the composition (guluronic acid/mannuronic acid ratio) and molecular weight among others are critical factors affecting the physical properties of the resultant hydrogels, such as the degradation behavior [15] ; however, although is known that the ratio effect of these two monomers plays some role in biocompatibility -alginate with higher guluronate content produced gels has been shown to be less biocompatible-, [16] its effect on bone regeneration remains unknown. Therefore, among different types of alginates we have chosen two sterile lyophilized alginates with high mannuronate and high guluronate content that have lower molecular weight (MW: 75 000-220 000 g mol −1 ) and lower viscosity than other commercial alginates (i.e., SLM-100 and SLG-100) based on the idea that injectable formulations can be obtained easier with lower viscosity alginates. In situ gelling formulations of alginates were developed via calcium complexation. HA is another linear polysaccharide consisting of repeating units of D-glucuronic acid and N-acetyl-D-glucosamine and is an abundant glycosaminoglycan in extracellular matrices. Therefore, injectable HA hydrogels have been used for bone regeneration in the presence of BMP-2. [17] However, to induce subcutaneous bone formation with HA, a very high dose of BMP-2 (150 µg mL −1 ) is normally used. [17b,18] Surprisingly, even when high doses of BMP-2 are supplied, HA has failed to induce bone formation. [17b] To optimize the performance of gels, those are often functionalized to engineer better delivery systems and that is also the case of HA and its derivations. Investigators have recently shown that HA gels functionalized with fibronectin formed more ectopic bone than its nonfunctionalized counterpart. [19] However, functionalizing HA did not always induce more bone formation. For example, heparin functionalization of HA led to less ectopic bone formation than its nonfunctionalized counterpart formation when implanted intramuscularly. [20] Another study examined the suitability of acrylated hyaluronic acid for tissue regeneration, concluding that it is as a potential carrier of cells and growth factors. [21] These studies showed that HA and alginates have potential for use in bone regeneration. However, choosing the right formulations of engineered materials with a right dose of BMP-2 is challenging. Additionally, a huge demand in bone regeneration field is the development of in situ gelling materials that enable slow protein release, support cell attachment, vascularization and thus induction of bone formation. In this study, we have used poly(N-isopropylacrylamide) functionalized hyaluronic acid (HApN) that shows thermoresponsive gelling behavior.
We aimed to develop in situ gelling formulations with natural polymers (alginate or HA) to retain the RCP-MS which would provide slow BMP-2 release and increase cell attachment. We also wanted to assess how the hydrogel matrices influence the in vitro release of BMP-2 from the microspheres and the bone induction in vivo. For that purpose, we have developed three different hydrogel-microsphere systems: two different thixotropic alginate formulations and a thermoresponsive (gelling above 32 °C) HApN. The three distinct formulations are different in terms of chemical composition, crosslinking www.advancedsciencenews.com www.advhealthmat.de and physical/mechanical properties. Here we aimed to assess them in terms of their ability to support bone formation acting as a growth factor slow release system. Thus, the function of these gels is to be injectable, in situ gelling, provide a sustained release of BMP-2 and ultimately induce de novo bone formation. The mechanical properties of these gels and BMP-2 release characteristics in vitro were evaluated. The bone formation ability of these materials was studied in an ectopic bone formation model in vivo. The volume and morphology of the ectopic bone, vascularization, cellular infiltration and inflammation were evaluated.
Results

RCP Microsphere-Alginate In Situ Gelling Hydrogels Have Shear-Thinning Behavior
Strain-dependent oscillatory rheology of RCP microsphere-alginate hydrogels showed an extremely broad linear viscoelastic region in addition to network rupture at high strains for the alginates containing 8% microspheres (Table 1 and Figure S3 , Supporting Information). The SLG alginate with microspheres (SLG + 8% microspheres) broke at 150% strain whereas the formulation containing glucono-delta-lactone (GDL, which allowed release of Ca 2+ ions to enable the crosslinking of the alginate) (SLG + 8% microspheres + GDL) was not broken at the maximum strain measured, 167% (Table S1 , Supporting Information). This demonstrates that addition of GDL to the formulation, releasing 3.18 × 10 −6 m Ca 2+ ions (Table 1) , improved the mechanical properties of the SLG gel as a result of the release of Ca 2+ ions that allowed alginate crosslinking. The viscoelastic region was much smaller for the control consisting of alginate, CaCO 3 particles (1 µm) and GDL. This formulation was broken at 40% strain showing the reinforcing effect of the microspheres in the formulation. GDL was not required for the crosslinking of the SLM alginate. Interestingly, the optimized formulations of SLM+MS and SLG+MS were thixotropic. When 500% strain was applied, a decrease in both loss and storage moduli was observed and the hydrogel structure was broken showing the shear-thinning effect ( Figure 1A) . When the stress was removed, the hydrogel recovered almost instantaneously indicating that the gel can be formed in situ directly after injection in vivo. This cycle can be repeated several times without loss of function. Both of the alginates were injectable due to this shear thinning behavior. The formed hydrogels had storage (elastic) moduli between 1-2 kPa for both alginate gel formulations.
The surface morphologies of the freeze-dried formulations were examined by scanning electron microscope (SEM).
Polymer scaffolds for tissue engineering must be highly porous to permit the infiltration of a large number of cells and their differentiation in situ. Dry average diameter of RCP-MS was ≈70 µm and the formulations studied-alginate SLM, alginate SLG, and HApN-formed an interconnected pore network with the RCP-MS homogenously distributed throughout it ( Figure 1C) . Table 1 indicates the composition of the formulations used. The aim was to find the optimal formulation with the minimum of fabrication steps with our desired characteristics that would lead to maximum bone formation in vivo.
HApN-Microsphere Formulation Have Thermoresponsive Behavior
HApN hydrogel grafted with PNIPAM has an intrinsic property of thermoinducible gel formation as shown earlier by D'Este et al. [22] In combination with microspheres the thermoresponsive behavior was retained, which can be seen by the mechanical characterization of the hydrogel at increasing and decreasing temperatures between 15 and 40 °C ( Figure 1B ). In the cooling phase, there was a change from the gel state to the liquid state whereas in the heating phase, liquid to gel transition occurs. Both the storage modulus and loss modulus of the formed gel increased to 5 kPa at 37 °C.
BMP-2 Release from HApN-MS Hydrogel Was Lower than Alginate-MS Hydrogels
Apart from the injectability of the hydrogel, the ability of the hydrogels to provide sustained BMP-2 release is important for bone formation. We have showed earlier that there is a specific interaction between BMP-2 and RCP. [10c] Here, the release of BMP-2 from the hydrogels+RCP-MS formulations was studied and compared to hydrogel or RCP-MS only conditions. Both alginate hydrogels with RCP-MS released BMP-2 slower than alginate without RCP-MS, showing the synergistic effect of microspheres and hydrogels to control the release (Figure 2A) . During the time-course study of two weeks, ≈10% of BMP-2 (202 ± 42 ng; mean ± SD) was released from SLG+RCP-MS formulation and only ≈2% (46 ± 23 ng; mean ± SD) was released from SLM+RCP-MS formulation. The numbers indicated that the majority of BMP-2 was retained in the alginate-RCP-MS formulations. These results suggest that a similar slow-degradation of the RCP-MS will also occur in vivo as observed by the gradual shrinkage and breakdown of the microspheres over time.
In the HApN formulation, RCP-MS without CaCO 3 addition were used. Although the RCP-MS without calcium are Figure S1 , Supporting Information), no differences in BMP2 release were observed when compared HApN and HApN+RCP-MS. The release from the HApN+MS and from HApN hydrogel only was limited ( Figure 2B ) and the total release was less than 0.2% (3.7 ± 0.4 ng and 4.2 ± 0.2 ng), a fraction of the 3.3 µg loaded into the gels. To confirm that the unreleased BMP-2 was still inside the hydrogel after 2 weeks, ten times diluted samples were loaded on an SDS-PAGE gel ( Figure S4 , Supporting Information). We could detect a band of BMP-2 after 2 weeks of release, which confirmed that HApN hydrogel was preventing BMP-2 release. www.advancedsciencenews.com www.advhealthmat.de BMP-2 were used as controls. 1 week postinjection, histology revealed noticeable differences in terms of composite integrity between formulations ( Figure 3A ). In the alginate formulations, both the microspheres and the alginate layer were mostly intact, with some cellular infiltration in the fissures that appeared in the gel. However, in the HApN+RCP-MS formulation, much of the hydrogel had disappeared, many of the microspheres were being degraded and numerous cells could be observed within the implants ( Figure 3A ). After 4 weeks, bone formation was observed in one third of the alginate harvested formulations ( Figure 3A ). Bone formation was analyzed by micro-CT. No mineralization was observed 1 week after implantation. A similar amount of calcified tissue in all three hydrogel formulations tested was observed at 4 weeks postimplantation ( Figure 3B ,C). Interestingly, in the alginate formulations cartilaginous regions were found at that time point, suggesting that endochondral ossification process was occurring near by the RCP+RCP-MS ( Figure S5 , Supporting Information). At 10 weeks, micro-CT confirmed the greatest amount of bone formation when alginate SLG was used as a carrier, showing a more than three-fold increase compared to the 4 weeks scan (mean ± SD, from 4.4 ± 5.4 mm 3 mineral volume at 4 weeks to 22.3 ± 11 mm 3 at 10 weeks). When alginate SLM+RCP-MS or thermoresponsive HApN+RCP-MS were used, the amount of calcified tissue found within the implants did not change significantly over time ( Figure 3B ). Moreover, the alginate SLG+RCP-MS formulation significantly increased the amount of mineral volume formed at 10 weeks compared to alginate SLM (22.3 ± 11 mm 3 vs 4.24 ± 3 mm 3 ) ( Figure 3B ). As we expected, when alginate formulations were implanted without BMP-2, mineral tissue was barely found ( Figure 3C ). Interestingly, the thermoresponsive HApN+RCP-MS formulation showed calcified tissue on micro-CT, even without the addition of BMP-2 ( Figure 3C ), but histological analysis did not show bone formation and the formulation structure was almost degraded with or without BMP-2 addition at the end of the experiment ( Figure 3A ).
Injectable BMP-2 Loaded Hydrogel Formulations Induced Ectopic Bone Formation
Inflammatory Cell Infiltration Decreased over Time in Alginate in Comparison to Hyaluronan Formulations
To investigate the role of inflammation in the bone formation process, we used cluster of differentiation 68 (CD68) as a general marker to identify cells of the macrophage lineage. We observed a significant time dependent decrease in staining in the alginate SLG (median ± 95% CI, 39 ± 8.3 at 1 week vs 7 ± 7.5 at 10 weeks, p < 0.05) ( Figure 4A,B) . In the alginate SLM+RCP-MS formulation CD68-positive staining was less pronounced than in SLG+RCP-MS at week 1, increased at week 4 and then significantly dropped again at week 10 (mean ± 95% CI, 14 ± 3.9 at 1 week and 33.5 ± 7.3 vs 10 ± 11 for 4 and 10 week rank, respectively). In the HApN+RCP-MS formulation, macrophage recruitment was slower than in alginate SLG+RCP-MS formulation and had the highest CD68-positive staining at 10 weeks (median ± 95% CI, from 23.5 ± 6.3 at week 1 to 48.5 ± 5.5 at the end of the experiment, p < 0.01) ( Figure 4A ,B). Furthermore, when we compared the formulations to each other at 1, 4 and 10 weeks postimplantation, the SLG+RCP-MS formulation showed more pronounced infiltration of CD68-positive cells at 1 week than SLM+RCP-MS (39 ± 8.3 vs 14 ± 3.9, p < 0.01) and CD68-positive staining at 10 weeks in the HApN+RCP-MS formulation was significantly higher than in both, alginate SLM+RCP-MS and alginate SLG+RCP-MS (10 ± 11 for SLM+RCP-MS, 7 ± 7.5 for SLG+RCP-MS vs 48.5 ± 5.5 for HApN+RCP-MS, p < 0.05).
To further investigate whether the different formulations promoted the activation of distinct macrophage phenotypes, proinflammatory (M1) and anti-inflammatory (M2) macrophage subsets were identified. To achieve this, inducible nitric oxide synthetase (iNOS) and cluster of differentiation 206 (CD206) markers were used. iNOS, was used as marker for M1 macrophages. The HApN+RCP-MS formulation had significantly more iNOS-positive staining compared to the alginate SLG+RCP-MS formulation at 10 weeks (median ± 95% CI, 41.25 ± 9.6 vs 7 ± 8.8, p < 0.05) ( Figure 4C ). CD206-positive staining to identify M2 macrophages did not show any difference between formulations at week 1. At 4 weeks, CD206-positive staining was significantly higher in SLM+RCP-MS than in HApN+RCP-MS formulations (28.2 ± 4 vs 10.5 ± 4.2). At week 10 no significant differences were found between them ( Figure 4D ). www.advancedsciencenews.com www.advhealthmat.de
Injectable Formulations Loaded with BMP-2 Promoted Blood Vessel Ingrowth
Vascularization is a prerequisite for ossification. In all three formulations blood vessel density increased over time ( Figure 5A ). Interestingly the quantity of blood vessels found within the implants differed markedly between formulations, showing more than fivefold more vessels in the HApN+RCP-MS formulation-mean ± SD; 395 ± 82 counted at 10 weeks-compared to the SLM+RCP-MS-with 144 ± 79 at 10 week (p < 0.001) ( Figure 5A ,B). In addition, in SLG+RCP-MS and HApN+RCP-MS the quantity of blood vessels was significantly higher at 10 weeks than at 1 week (mean ± SD; 144 ± 79 vs 13 ± 16 in alginate SLG+RCP-MS, and 395 ± 82 vs 38 ± 27 in HApN+RCP-MS) ( Figure 5A ). Without BMP-2 no significant increase in the number of blood vessels were www.advancedsciencenews.com www.advhealthmat.de observed between 1 and 10 weeks in any of the formulations (data not shown).
Discussion
In this study, we have developed three different sustainedrelease formulations with different physical and chemical properties to be used in bone tissue engineering. We have tested in situ gelling HApN formulation with thermoresponsive behavior and two alginate formulations with shear-thinning behavior as potential systems for the induction of de novo bone formation. We have found differences in the BMP-2 release pattern when loaded in HApN versus alginate hydrogels. Also, a further decrease in release rate was observed when BMP-2 was absorbed to +RCP-MS and then combined with alginate hydrogels. Furthermore, we have shown that the slow-release gel-microsphere system comprised of SLG alginate supported the essential processes needed for bone formation, such as inflammatory cell infiltration, vascularization and osteogenesis in vivo and was superior to the SLM alginate and HApN formulations. Through analysis of the phenotype of the infiltrating cells and kinetics of blood vessel invasion we shed some light on the possible reasons for the differences observed between formulations. Injectable matrices have been the subject of much research in the fields of drug delivery and tissue engineering due to the minimally invasive nature with which they can be delivered. [3] We selected alginate and HApN formulations as carriers of RCP-MS for two reasons. First, they are both natural-origin polymers that are commonly used for bone regeneration; second, they can form in situ gelling systems. The in situ hydrogel forming ability of PNIPAM functionalized HA and alginate has already been shown. [22, 23] However, the formulations with microspheres are novel and were developed specifically for this study. One advantage of the system with alginate is that it can form a reversible hydrogel (thixotropic) which has not been observed in other in situ gelling alginates. [24] This reversible behavior of the gel makes handling much easier since the hydrogel can be prepared in advance and stored prior to www.advancedsciencenews.com www.advhealthmat.de application. Another advantage of both types of alginate formulations used in this study was the gelation time, which was so quick that the formed gel stayed in the injection site. In addition, the relatively slow degradation time of the alginates matched the time required for bone formation. The alginates showed some signs of initial degradation on histology by the first week, but after 10 weeks hydrogel was still present, which kept the microspheres and protein at the site, supported the formation of new bone and delayed the release of BMP-2. It is still controversial what the ideal BMP-2 release kinetics are to successfully form bone. Some studies have shown BMP2-mediated bone formation was not influenced by the release timing, while others demonstrated that in ectopic sites sustained release significantly enhanced bone formation compared to burst release. [14, 25] BMP-2 is chemoattractant to osteoprogenitor cells [26] and it is generally accepted that the delivery vehicle should maintain BMP2 concentration within the therapeutic frame for enough time to allow recruitment and differentiation of osteoprogenitor cells. Therefore, the type of hydrogel chosen is important. In our study, the diffusion of BMP-2 seems to be faster in the SLM alginate than in the SLG hydrogel. However, when loaded in the microspheres the opposite happens, being faster the release in the SLG formulation. The slightly acidic environment initially created with GDL, might have solubilized BMP-2 more and led to more release. Previous publications have also shown that using microsphere/ hydrogel combinations slows down protein release compared to the use of only hydrogels. [27] Our results are in agreement with those studies as we have observed 20% more BMP-2 retention when SLG and SLM were combined with RCP-MS. We have previously shown that the RCP-MS can only be degraded by collagenase treatment due to the highly cross-linked network and that when particles are fully degraded, BMP-2 could be released from the RCP-MS. [10c] Collagenase is crucial for the remodeling of collagenous extracellular matrices, including bone tissues and it is expressed by both osteoblasts and osteoclasts. [28] These findings suggest that the collagenase expressed by the infiltrating cells might be an important factor for bone formation. In our study, it might have been also relevant for in vivo BMP-2 release from the RCP-MS and may have been a determining factor in the differences in bone formation observed between formulations. SLG+RCP-MS lead to more BMP-2 release than SLM+RCP-MS resulting in more bone formation. When HApN was used as a hydrogel, with or without the addition of RCP-MS, most of it was retained and no bone formation was observed. These data suggest a smaller pore size of HApN hydrogel due to higher molecular weight and initial dry content or a strong interaction between thermoresponsive HApN hydrogel and BMP-2 resulting in the retention of the protein. This has been observed previously for HA. In one study, HAbased powder gel composite showed slow release of less than 20% of the total amount of rhBMP-2. [29] Most likely this lack of release prevented the attraction of the necessary cells at the early stages and by the time it had been released the material was too degraded to modulate the release rate or structurally support bone formation. Whether this affinity for BMP-2 is specific to PNIPAM functionalized HA or is a more general phenomenon requires further investigation. It is important to mention that in alginate formulations calcium carbonate was added to crosslink the hydrogels and therefore, calcium ions could still be present during the experiment. It has been widely demonstrated that the addition of calcium ions enhances the osteogenic capacity of osteoprogenitor cells and the overall bone formation and, consequently, might have a positive effect in the outcome observed when alginate formulations were used in this study. However, it is unlikely that the significant difference in terms of bone formation between the different slowrelease systems tested is only due to the presence of calcium ions, but to their physical properties such as stiffness or degradation rate.
The mechanical properties of the alginates showed that the storage (elastic) moduli are in the range of elastic moduli of endothelial tissue and stromal tissue. [30] However, the elastic modulus of HApN with microspheres is higher than that of alginates and comparable to elastic modulus of a smooth muscle. [30] These mechanical properties indicate that the gels can retain the microspheres in situ, fill a defect and provide initial support during the formation of bone. The mechanical properties of these thixotropic alginate hydrogels (1-2 kPa) are similar to non-in situ gelling alginates. [31] According to Banerjee et al., gels with very high elastic moduli are undesirable and thixotropic gels with moderate elastic moduli (which were what we used in this study) should be suitable for bone regeneration. [32] With regard to HA, 50% crosslinked HA had an elastic modulus of 30 Pa, [33] which is far lower than the PNIPAM functionalized hydrogel presented in this study (5 kPa). After bone fracture, following the initial inflammation a callus forms. The mechanical properties of fracture callus have been measured and found to depend on multiple tissue types: the range of the indentation moduli was 0.61-1.27 MPa (median = 0.99 MPa) for granulation tissue, 1.39-4.42 MPa (median = 2.89 MPa) for chondroid tissue and 26.92-1010.00 MPa (median = 132.00 MPa) for woven bone. [34] We therefore concluded that an elastic modulus in the range of 1-10 MPa is suitable for supporting the regenerative tissue. Given the mechanical properties of these hydrogels, it could be feasible to apply them directly to repair nonload bearing bone defects. For fractures or defects in the load bearing bones, the application would still require some other kind of mechanical stabilization, be that a traditional cast, internal fixation or combination with other stronger biomaterials.
HA is a commonly used material for cartilage regeneration. Eglin et al. found that thermoresponsive HApN can be used to support hMSCs for the treatment of degenerated intervertebral disc and therefore HA hydrogels were developed as a bone-cartilage interface. [35] Injectable HA has been shown to be successful in a rabbit osteochondral defect model. [36] Interestingly, one study suggested that HA might impede bone formation by inhibiting osteoblast differentiation. [37] Maus et al. used combinations of commercially available injectable HA with and without 200 µg BMP-2 in a sheep femoral defect. However, none of the conditions resulted in significant bone formation. [17b] Bakhta et al. used hyaluronan-based hydrogels loaded with 5 µg BMP-2 ectopically and observed significant bone formation within the formulations and a mineral volume of 4.4 ± 0.5 mm 3 after 8 weeks. [38] However, prior to our study, in situ gelling HA had never been used in combination with particles to enhance cell adhesion and to promote bone www.advancedsciencenews.com www.advhealthmat.de tissue formation. We used microspheres rich in RGD motifs as BMP-2 carrier and failed to show bone formation after 10 weeks. Unlike Bakhta et al., who implanted the formulations intramuscularly, which is more conducive to supporting de novo bone formation, we injected our formulation subcutaneously and this might account for the discrepancy observed. How to modulate inflammation has become a hot topic in bone repair in the past decade. [39] Several groups have studied both the influence of different biomaterials upon macrophage polarization in vitro [40] and the positive dose-dependent relationship between the dosage of BMP-2 and the inflammatory volume. [41] Most in vivo bone formation studies have investigated the inflammatory response involved by using a single marker to identify monocyte-macrophage-osteoclast cells such as TRAP or have relied on generic histology (e.g., hematoxylin and eosin (H&E)) to assess inflammation. [41a,b,42] In our study, we used CD68, iNOS and CD206 as markers to identify macrophage presence and to indicate their phenotype within our tested formulations. The BMP-2 dose used in this study was low, to prevent potential side-effects associated with higher doses (such as inflammation), to allow us to better investigate the effects of the materials. We observed a late CD68+ cell infiltration in the HApN+RCP-MS formulations, which increased over time. It has been reported that macrophages can specifically recognize HA through receptors such as CD44 or the hyaluronan receptor for endocytosis, HARE [43] and that the HA-CD44 interaction is involved in multiple cellular functions such as inflammation. [44] This might explain the high levels of inflammatory cell infiltrate observed at the later time points in the HApN+MS group. In contrast, in alginate formulations, CD68+ staining was lower at 10 weeks than at 1 week, and bone formation was successfully achieved. It is known that alginates from wound dressings interact with wound macrophages [45] and alginate-collagen formulations have been shown to locally integrate with host tissue in an abdominal wall defect model. [46] Several studies have shown that the mannuronic acid residues of soluble alginate are cytokine-stimulating to monocytes. [47] In our study, at 4 weeks, there was more CD206+ staining in the alginate formulations, especially in the alginate SLM, than in the HApN+MS formulation. These data suggest a possible polarization of the monocytes toward the anti-inflammatory/ tissue remodeling M2 phenotype. Moreover, there were significantly more iNOS+ cells in the HApN+RCP-MS formulation than in the alginate formulations at 10 weeks, which is more indicative of a proinflammatory situation. Taken together the results suggest that within alginate formulations there was an initial inflammatory phase that resolved over time, leading to bone formation. In contrast, in the HApN+RCP-MS formulation the presence of proinflammatory cells increased over time and there were with significantly fewer anti-inflammatory CD206 positive cells. This likely also negatively influenced the bone formation process in the HApN+RCP-MS gels.
Vascularization is another critical factor for successful bone formation. It has been demonstrated that HA-based scaffolds promote angiogenesis when used in a wide variety of applications, such as abdominal wall defect repair, brain injury or heart disease models. [48] Moreover, Cui et al. demonstrated the ability of HA-RGD scaffolds to support angiogenesis in the cortex of the brain. [49] Similarly, alginate-based beads loaded with VEGF had been used subcutaneously for bone tissue engineering, promoting angiogenesis. [50] Furthermore, a study in which alginate and alginate-RGD hydrogel were injected into the infarct area of rats showed that both increased arteriole density but that the greatest angiogenic response was in the alginate-RGD hydrogel condition. [51] Our findings agree with the results obtained in previous studies and we have demonstrated that both thermoresponsive HA and alginate enriched with RGD MS are able to promote vasculature formation ectopically when loaded with BMP-2. It is, however, clear that in this case more does not necessarily mean better: although significantly more vessels were present in the HA implants than in the alginates, this did not lead to the formation of any bony tissue.
Conclusions
In situ gelling hydrogels encapsulating BMP-2 loaded RCP-MS represent an injectable slow-release protein delivery system. Alginate formulations effectively promoted bone formation in an ectopic model. While there was successful infiltration of cells into all three formulations, differences between materials were observed in the macrophage phenotype and invasion kinetics. Also, while there was ample vascularization in all three materials there were clear differences in the total number of blood vessels with the higher number present in the HA formulation not increasing the success of de novo bone formation. Thus, alginate SLG combined with RCP-MS and loaded with low dose BMP-2 displayed optimal protein release rate, cellular invasion, material degradation rate and vascularization kinetics to support bone formation. This study presents a novel cell-free injectable slow-release system that has potential as a void-filling material for the induction of new bone formation.
Experimental Section
Materials: Human collagen type I based recombinant peptide (RCP) is a product of Fujifilm commercially available as Cellnest. It is produced in a fermentation process by genetically modified yeast Pichia pastoris as described elsewhere. [10a,52] RCP is composed of 571 amino acids; it has an isoelectric point (pI) of 10.02 and a molecular weight of 51.2 kDa. BMP-2 was produced as described previously [53] and it was kindly provided by Dr. Joachim Nickel (Fraunhofer IGB, Germany). Pronova SLM20 (G/M ratio: ≤ 1, sterile alginate, viscosity: 20-99 mPa s, MW: 75-150 kDa,) and Pronova SLG20 (G/M ratio: ≥ 1.5, sterile alginate, viscosity: 20-99 mPa s, MW: 75-150 kDa, G/M ratio: ≤ 1) were ordered from Novamatrix (Sandvika, Norway). Thermoresponsive HApN (MW: 1.68 MDa) consisting of HA grafted with PNIPAM was prepared as described in D'Este et al. [22] Hexamethylene diisocyanide (HMDIC), corn oil, sodium chloride, calcium carbonate (CaCO3), and GDL were purchased from SigmaAldrich (St. Louis, MO, USA). Ethanol, acetone, and hydrochloric acid were purchased from Millipore (Billerica, MA, USA). ELISA development kit and reagents for BMP-2 determination were ordered from Peprotech (Rocky Hill, NJ, USA). Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), and penicillin-streptomycin (P/S) were ordered from Thermofisher Scientific (Waltham, MA, USA).
RCP Microsphere Preparation:
The types of RCP-MS used in this study were selected based on a previous study in which the adsorption of BMP-2 to the RCP-was described, [10c] as well as the effect of BMP-2 concentration, RCP-MS size, porosity, and cross-linking of the RCP-MS www.advancedsciencenews.com www.advhealthmat.de on BMP-2 release. Based on this study, HMDIC cross-linked RCP-MS with a range of diameter 50-75 µm were selected as a promising candidate in terms of slow-release of BMP-2. RCP-MS were produced by emulsification using calcium carbonate (CaCO 3 ). Briefly, a 20% aqueous RCP solution was prepared and mixed with CaCO 3 fine powder (with a size of <1 µm) in a 1:1 (w/w) ratio of RCP to CaCO 3 . This suspension was emulsified in corn oil at 50 °C. After cooling, the emulsified microspheres were precipitated and washed three times with acetone, and subsequently dried overnight at 60 °C. The microspheres were sieved to 50-75 µm size (Retsch GmbH, Germany). Particles were then cross-linked by HMDIC by mixing 1 g of spheres and 1 mL of HMDIC in 100 mL ethanol for 1 day while stirring. Excess crosslinker was removed by washing several times with ethanol after which the particles were dried at 60 °C. The particles used for the alginate and HApN formulations were prepared in identical way except that, for the HApN formulation, CaCO 3 was removed after the crosslinking step. For the alginate formulations the CaCO 3 was left in as the Ca 2+ also serves to cross-link the alginate into a hydrogel. For the HApN formulation CaCO 3 was removed by suspension of RCP-MS in 0.23 m hydrochloric acid for 30 min, followed by repeated washing with water until a neutral pH was achieved, and the RCP-MS were dried at 60 °C. Complete removal of the calcium was confirmed by EDX mapping ( Figure S1 , Supporting Information). The morphology of CaCO 3 containing and CaCO 3 free microspheres was analyzed by scanning electron microscope (SEM) (Jeol JSM-6335F Field Emission Scanning Electron Microscope) ( Figure S2 , Supporting Information). CaCO 3 crystals clearly can be observed on the surface of the CaCO 3 comprising microspheres ( Figure S1 , Supporting Information). Particles were gamma sterilized at 25 kGray (Synergy Health, The Netherlands) prior to use in vitro and in vivo.
Preparation of the Hydrogel Formulations: To prepare the formulations with SLM20 and SLG20 alginates, alginates were dissolved in 0.9% sterile sodium chloride to create 2% w/v solution. 68 mg of calcium comprising microspheres were incubated overnight at 4 °C with 170 µL of 122.5 µg mL −1 BMP-2. The following day, the swollen particles were mixed with 1014 µL of SLM or SLG solution. Alginates have the ability to form soft hydrogels in the presence of calcium ions; however, although the calcium carbonate released by the microspheres was enough to crosslink the alginate SLM, it was not enough to crosslink alginate SLG. Table 1 shows the composition of the formulations. Calcium ions released in the SLM formulation were below the detection limit of the colorimetric assay. In the final SLG formulation, more calcium ions (3.18 × 10 −6 m) were released. Therefore, in order to crosslink alginate SLG, GDL, was used. GDL has been combined with alginate extensively to obtain an injectable gel with optimal mechanical properties. [54] GDL is normally used as an acidifier and it was added to alginate SLG formulation in order to release more calcium ions from the CaCO 3 upon gradual hydrolysis of GDL to gluconic acid and therefore increase the mechanical properties of SLG formulation. Briefly, to the SLG formulation, 106 µL of 0.06 m freshly prepared GDL solution was added and mixed immediately. GDL was used to dissolve minute amounts of CaCO 3 so that alginate can be crosslinked and increase the mechanical properties of the formulation. In parallel, 106 µL of 0.9% sodium chloride was added to the SLM formulation for which it was not necessary to add GDL as shown by rheology. The formulations were thoroughly mixed and immediately and incubated overnight at 4 °C to equilibrate. One day later, prepared formulations were mixed again prior to injection in vivo or to use for in vitro experiments. For both in vivo and in vitro experiments 200 µL of the prepared formulations were used. The final amount of BMP-2 was 3.3 µg in each 200 µL hydrogel+RCP-MS formulation (Table 1) . Solubilized Ca 2+ ion as shown in µM and % in Table 1 was detected by calcium colorimetric assay following the manufacturer's instructions (Sigma-Aldrich).
The following formulations were used for in vitro and in vivo experiments. First, a 15% w/w solution of HApN was prepared in PBS. On the same day, 170 µL BMP-2 at 122.5 µg mL −1 concentration was added to 34 mg of RCP-MS (without CaCO 3 ) and particles were incubated at 4 °C overnight. The next day, 850 µL HApN (15% w/w) and 270 µL PBS were added to the swollen particles and the formulation was mixed with a 1 mL syringe and 19 G needle. The composition of the final formulations is shown in Table 1 . In order to keep the amount of RCP the same in all different formulations, half of the microspheres were used in HApN condition compared to SLM+RCP-MS or SLG+RCP-MS formulations that contained 50% CaCO 3 and 50% RCP in the microspheres. The prepared formulations were mixed and incubated overnight at 4 °C to equilibrate. All formulations were prepared under sterile conditions. Biomineralization of the hydrogels formulations was not studied, since interactions between RCP-MS and hydrogels were not expected to change the mineralization properties of the formulation. [10b,12] Characterization of the Formulations: The mechanical properties of prepared hydrogels containing BMP-2 loaded microspheres were measured by a rheometer (Anton Paar MCR301, Austria). A 20 mm diameter parallel plate measuring system was used. After sample addition to the plate, silicon oil was applied to the edges to prevent evaporation. All measurements were performed with a normal force of 0.1 N. As a precharacterization, the storage (or elastic) modulus (G′) and loss (or viscous) modulus (G″) were measured at different strains to determine the linear viscoelastic region. To determine the linear viscoelastic region in alginate formulations (shown in Table S1 , Supporting Information) four different formulations were prepared. SLG alginate (1.5%, w/v); SLG alginate (1.5%, w/v) with microspheres (8%, w/v); SLG alginate (1.5%, w/v) with microspheres (8%, w/v) and GDL (5 × 10 −3 m); and SLG alginate with CaCO 3 (4%, w/v) and GDL (5 × 10 −3 m) were prepared. After precharacterization, thermosensitive HApN+RCP-MS formulation was measured at 2% strain, at 1 Hz while heating from 15 to 40 °C followed by cooling from 40 to 15 °C.
Alginate formulations were measured by a two-step repeating cycle. At the first step of the cycle, storage, and loss moduli were measured at 1% strain, at 1 Hz, at 37 °C. At the second step, 500% strain, 1 Hz frequency, 37 °C temperature was applied. The cycle repeated four times to characterize thixotropic behavior. During the measurements, perturbations due to collisions and cantings of the particles were not observed.
The morphology of the formulations was investigated by using SEM. To prepare the samples prior to analysis, RCP-MS loaded hydrogels were immersed into liquid nitrogen and freeze-dried at −50 °C. The crosssection of the formulations was sputter-coated with gold before loading onto the microscope.
Release of BMP-2 from Hydrogel Formulations: The formulations containing hydrogels and BMP-2 loaded microspheres were prepared as described above. 200 µL of hydrogel formulations was added to 24 well plate inserts with 0.4 µm pore size. 1 mL DMEM with 10% FBS and 1% P/S per well was added to the reservoir plate. The plates were incubated at 37 °C under constant agitation at 300 rpm. When removed from the incubator, the plates were put on a hot plate at 37 °C to prevent the gel-sol transition of HApN hydrogels. At each time point 1 mL medium was collected and changed with fresh medium. The collected release media were analyzed by rhBMP-2 ELISA development kit (Peprotech) according to manufacturer's protocol. As a positive control, 200 µL of 16.5 µg mL −1 BMP-2 solution was added to the inserts and 1 mL medium was added to bottom wells of the transwell plate. At each time point 1 mL medium was collected and changed with fresh medium. The cumulative amount of BMP-2 that passed through the membrane to the bottom of the well after 14 days was quantified. This control was included in order to study the effect of protein sticking to the plate and membrane, as well as its degradation over time. At the end of the experiment (Day 14), 2.3 µg ± 0.1 µg (mean ± SD, n = 3) cumulative release was detected from the positive control which was 3.3 µg BMP-2 initially added to the inserts of the transwells.
Conditions for Animal Experiment: All animal experiments were performed with prior approval of the ethics committee for laboratory animal use (protocol #EMC 116-15-01). To have a statistically relevant group size, we performed a power analysis with an alpha of 0.05 and power = 80%. Based on similar works performed in an ectopic model using comparable cell-free systems, [55] we expected a difference in bone formation of ≈25 mm 3 and an SD of ± 15 mm 3 . Therefore, 34 male www.advancedsciencenews.com www.advhealthmat.de Sprague Dawley (SD) rats at 12 weeks old were used in this study to evaluate bone formation. The animals were randomly assigned and housed in pairs in a specific pathogen-free environment and allowed to adapt to the conditions of the animal house for 7 days before starting the study. The animals were maintained at 20-26 °C on a 12 h dark/light cycle with ad libitum access to standard rat chow and water. To evaluate the effect of BMP-2 loaded in the different formulations, RCP-MS with a constant concentration of rhBMP-2 (3 µg per injection) and incorporated in SLG, SLM, or HApN hydrogels were subcutaneously injected (total volume 200 µL per injection) in the dorsum of the animals. As controls, SLM+RCP-MS, SLG+RCP-MS, and HApN+RCP-MS were implanted without BMP-2 addition. N = 6 replicates were used for each condition and each animal received six randomly assigned injections. All injections were performed using a 19 gauge needle on animals under isoflurane inhalation. At 1, 4, and 10 weeks after implantation, animals were euthanized with CO 2 and the specimens were harvested for further analysis. To reduce the number of animals used in this study, controls were harvested at 1 and 10 weeks after implantation. Micro-CT Analysis: When animals were euthanized at 4 and 10 weeks following transplantation, retrieved implants were immediately scanned at a resolution of 9 µm, using a SkyScan 1172 system (Bruker, Belgium). The following settings were used: X-ray power and tube current were 40 kV and 0.25 mA, respectively. Exposure time was 5.9 s and an average of three pictures was taken at each angle (0.9°) to generate final images. These images were further reconstructed by SkyScan NRecon software (Bruker) using a range of 0-0.1 on the histogram scale, 20% beamhardening correction and ring artefact reduction with a value of 5. For image processing SkyScan CTAnalyser software (Bruker) was used. Threshold levels of 120 (lower) and 255 (higher) were set to extract the amount of mineral volume from the tissue volume (BV/TV).
Histology: For histological examination, specimens were fixed in 4% formalin solution for 48 h and decalcified with 10% w/v EDTA for 2-4 weeks. Implants were dehydrated and embedded in paraffin. Sections of 6 µm thickness were prepared using a microtome and mounted on subbed glass slides (StarFrost, Knittel Glass, Germany). Three selected cross sections from each implant, with a minimum distance of 120 µm apart were deparaffinized and rinsed with distilled water to be stained with H&E. The sections were imaged by NanoZoomer-XR (Hamamatsu, Japan). A square grid (400-800 µm) overlay was used to quantify newly formed blood vessels, which were identified based on the presence of erythrocytes within a tubular-like structure. The number of blood vessels was counted within the implants in a blinded fashion by two examiners and averaged.
CD68 marker was used to distinguish cells of the macrophage lineage, iNOS and CD206 markers were used for detection of M1 and M2 macrophage subsets. For detection of CD68, iNOS, and CD206 positive cells, sections were deparaffinized and washed. In the case of CD68 and CD206, antigen retrieval was performed using a citrate buffer (10 × 10 −3 m, pH 6.0) at 90 °C for 20 min. For iNOS, 10 × 10 −3 m Tris, pH 9.0, 1 × 10 −3 m EDTA Solution, 0.05% v/v Tween 20 buffer was used. To avoid nonspecific binding, slides were preincubated 30 min with 10% v/v normal goat serum (NGS) (Southern Biotech, USA) in PBS/1%BSA w/v and 2% w/v milk powder to block nonspecific binding followed by 1 h incubation with either primary CD68 antibody (Acris, Germany) diluted to 0.5 µg mL −1 , primary CD206 antibody (Abcam, UK) diluted to 2.5 µg mL −1 or primary iNOS antibody (Abcam) diluted to 2 µg mL and analyzed using confocal microscope. Mouse IgG1 antibody (Dako Cytomation, Denmark) and rabbit IgG1 (Dako Cytomation) were used as negative controls.
Type II collagen occurs exclusively in cartilage, therefore, to investigate the presence of cartilaginous tissue within the formulations, collagen II staining was performed on the samples as previously described. [56] After Nanozoomer-XR imaging Hamamatsu Photonics, all the retrieved implants were ranked for CD68, iNOS, and CD206-positive cells in terms of both staining intensity and number of cells stained by two observers who scored all stainings and were blinded with regard to treatment. The results obtained by the two observers were averaged and rated on ordinal scale (lowest number = no/minor to highest number = moderate/heavy).
Statistical Analysis: To investigate whether there were differences in the number of blood vessels and CD68, iNOS and CD206 positive cells between conditions, a Kruskal-Wallis test was applied and Dunn's post hoc was used for analysis. Micro-CT quantitative data and BMP-2 release data were analyzed using one-way analysis of variance and Bonferroni's post hoc multiple comparison test was applied to the obtained results. A value of p < 0.05 was considered to be statistically significant.
Quantitative data are presented as bars, indicating the mean ± SD, while qualitative data are presented as box plots, indicating median, and the interquartile distance with the whiskers showing the largest and smallest values.
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